Daraxonrasib in metastatic pancreatic cancer (RASolute 302): survival breakthrough or real-world access barrier?

Qaseem M, Khan E, Hasan AH

DOI: 10.1097/ms9.0000000000005214
Published: 2026 Jul
Container: Annals of medicine and surgery (2012)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/ms9.0000000000005214,
  title = {Daraxonrasib in metastatic pancreatic cancer (RASolute 302): survival breakthrough or real-world access barrier?},
  author = {Qaseem M and Khan E and Hasan AH},
  year = {2026},
  journal = {Annals of medicine and surgery (2012)},
  doi = {10.1097/ms9.0000000000005214},
  url = {https://doi.org/10.1097/ms9.0000000000005214}
}

RIS

TY  - JOUR
TI  - Daraxonrasib in metastatic pancreatic cancer (RASolute 302): survival breakthrough or real-world access barrier?
AU  - Qaseem M
AU  - Khan E
AU  - Hasan AH
PY  - 2026
JO  - Annals of medicine and surgery (2012)
DO  - 10.1097/ms9.0000000000005214
UR  - https://doi.org/10.1097/ms9.0000000000005214
ER  -

APA

M, Q., E, K., & AH, H. (2026). Daraxonrasib in metastatic pancreatic cancer (RASolute 302): survival breakthrough or real-world access barrier?. Annals of medicine and surgery (2012). https://doi.org/10.1097/ms9.0000000000005214

Source records

pubmed · retrieved 2026-11-11T00:54:16.471Z